SAB Biotherapeutics, Inc. (SABS) Income Tax Expense (Benefit) USD 2022 - 2023

Historical data

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
SAB Biotherapeutics, Inc. annual/quarterly Income Tax Expense (Benefit) history and growth rate from 2022 to 2023.
  • SAB Biotherapeutics, Inc. Income Tax Expense (Benefit) for the quarter ending June 30, 2023 was $0.000.
  • SAB Biotherapeutics, Inc. annual Income Tax Expense (Benefit) for 2023 was $0.000, a 100% decline from 2022.
  • SAB Biotherapeutics, Inc. annual Income Tax Expense (Benefit) for 2022 was $25.6 K.
  • SAB Biotherapeutics, Inc. annual Income Tax Expense (Benefit) for 2021 was $0.000.
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2023 $0 +$92.3 K Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-21
Q1 2023 $0 -$92.3 K -100% Jan 1, 2023 Mar 31, 2023 10-Q 2023-05-15
Q2 2022 -$92.3 K Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-21
Q1 2022 $92.3 K Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-15
* An asterisk sign (*) next to the value indicates that the value is likely invalid.